Sebnem Yucel

7PUBLICATIONS
13CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Liquid biopsiesPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Oct 04, 2025
Synergistic prognostic effect of the renin-angiotensin-aldosterone system and immune-checkpoint inhibition in advanced lung cancer: The SPERICIL study.

Safa Can Efil, Sema Nur Ozsan Celebi, Beste Ozturk

|Jul 21, 2025
Comparative efficacy of adjuvant FOLFOX vs. FLOT following neoadjuvant FLOT in patients with locally advanced gastric cancer.

Furkan Ceylan, Didem Şener Dede, Safa Can Efil

|Nov 25, 2024
What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

Burak Bilgin, Sebnem Yucel, Mehmet Ali Nahit Sendur

|Jun 11, 2024
A current comprehensive role of immune-checkpoint inhibitors in resectable non-small cell lung cancer: A narrative review.

Safa Can Efil, Burak Bilgin, Furkan Ceylan

|Feb 02, 2021
The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement.

Burak Bilgin, Mehmet Ali Nahit Şendur, Şebnem Yücel

|Jan 12, 2021
Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study.

Burak Bilgin, Mehmet Ali Nahit Sendur, Sebnem Yucel

Pageof 2

Frequent Collaborators

3 joint publications

Safa Can Efil

3 joint publications

Mehmet Ali Nahit Şendur

2 joint publications

Furkan Ceylan

1 joint publications

Didem Şener Dede